Two new anticoagulants available in 2010 - Dabigatran Etexilate and Rivaroxaban: Expected progresses - raised problems;Deux nouveaux anticoagulants disponibles en 2010 - Dabigatran Etexilate et Rivaroxaban: Progrès attendus - problèmes posés

Annales Pharmaceutiques Francaises

Volumn 68, Issue 6, 2010, Pages 359-369

  Samama, M ^a   Conard, J ^a   Horellou, M H ^a   Le Flem, L ^a   Guinet, C ^a   Depasse, F ^a  

^a HÔTEL DIEU   (France)

Author keywords

Anti IIa; Anti Xa; Dabigatran; Fondaparinux; New anticoagulants; Rivaroxaban

Indexed keywords

ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG MARKETING; DRUG TARGETING; HUMAN; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PROTHROMBIN TIME; SHORT SURVEY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; BLOOD COAGULATION TESTS; FACTOR XA; HUMANS; MORPHOLINES; PYRIDINES; THIOPHENES; THROMBIN;

EID: 78149467425     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.08.001     Document Type: Short Survey

References (37)

1. th Edition). Chest 2008, 134:474. American College of Chest Physicians.
2. th Edition). Chest 2008, 133(6 Suppl.):234S-256S.
3. Turpie A.G. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008, 29:155-165.
4. Samama M.M., Gerotziafas G. Les nouveaux anticoagulants. Ann Pharm 2007, 65:8585-8594.
5. Sanford M., Plosker G.L. Dabigatran Etexilate. Drugs 2008, 68:1699-1709.
6. Gerotziafas G., Samama M.M. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 2005, 11:3855-3876.
7. Samama M.M., Gerotziafas G.T. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010, 29:92-104.
8. Rezaie A.R. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism on inhibition and comparison with therapeutic heparins. Thromb Haemost 2003, 89:112-121.
9. Eriksson B.I., Borris L.C., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Dose-escalation study of Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007, 120:685-693.
10. Turpie A.G.G., Fischer W.D., Bauer K., Kwong L., Gent M., Misselwitz F An oral, direct factor Xa inhibitor - BAY 59-7939 - for prophylaxis against venous thromboembolism after total knee replacement: a dose-ranging study. J Thromb Haemost 2005, 3:2479-2486. for the ODIXa-KNEE investigators.
11. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar Ak, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
12. Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., et al. Extended duration Rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised-controlled trial. Lancet 2008, 372:6-8.
13. Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thrombo-prophylaxis after total knee arthroplasty. N Engl J Med 2008, 358(26):2776-2786.
14. Turpie A.G.G., Bauer K.A., Davidson B., Gent M., Kwong L., Lassen M.R., et al. Once-daily oral Rivaroxaban compared with subcutaneous enoxaparin every 12hours for thromboprophylaxis after total knee replacement: RECORD4. Blood 2008, 112. [ASH Annual Meeting Abstracts, abstract 35].
15. Turpie A.G.G., Lassen M.R., Kakkar A.K., Eriksson B.I., MIsselwitz F., Bandel T.J., et al. A pooled analysis of our pivotal studies of Rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: effect of symptomatic venous thromboembolism and death, and bleeding. Haematologica 2009, 94(suppl. 2):212.
16. Buller H.R. Once-daily oral Rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study. Blood 2009, 114. [ASH Annual Meeting Abstracts, abstract 2].
17. Walenga J.M., Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010, 64:956-967.
18. Eriksson B.I., Smith H., Yasothan U., Kirkpatrick P. Dabigatran Etexilate. Nat Rev Drug Discov 2008, 7:557-558.
19. Eriksson B.I., Dahl O.E., Rosencher N., et al. Oral Dabigatran Etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
20. Ginsberg J.S., Davidson B.L., Comp P.C., et al. The oral thrombin inhibitor Dabigatran Etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24(1):1-9.
21. Eriksson B.I., Dahl O.E., Rosencher, et al. Dabigatran Etexilate versus enoxaparin of prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
22. Wolowacz S.E., Roskell N.S., Plumb J.M., Caprini J.A., Eriksson B.I. Efficacy and safety of Dabigatran Etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009, 101:77-85.
23. Eikelboom J.E., Weitz J.I. Dabigatran Etexilate for prevention of venous thromboembolism. Thromb Haemost 2009, 101:2-4.
24. Connolly S.J., Ezekowitz M.D., Yusud S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
25. Gage B.F. Can we rely on RE-LY?. N Engl J Med 2009, 361:1200-1202.
26. Hankey G.J. At last, a RE-LYable alternative to warfarin for atrial fibrillation. Int J Stroke 2009, 4:454-455.
27. Poller L., Jespersen J., Ibrahim S. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:2673-2675.
28. Schulman S., Eriksson H., Goldhaber S.Z., Kakkar A.K., Kearon C., Mismetti P., et al. Dabigatran Etexilate versus warfarin in the treatment of venous thromboembolism. Blood 2009, 114. [ASH Annual Meeting Abstracts, abstract 1].
29. Samama, Depasse F. Des anciens aux nouveaux anticoagulants: le rôle du biologiste. Ann Biol Clin 2009, 67:525-534.
30. Samama M.M., Martinoli J.L., Leflem L., Guinet C., Plu-Bureau G., Depasse F., et al. Assessment of laboratory assays to measure Rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
31. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. A new and specific rapid chromogenic anti-Xa assay for testing Rivaroxaban in plasma. In: 21st International Congress on Thrombosis. Milan; 2010.
32. Samama MM, Martinoli JL, Guinet C, Gourmelin Y, Perzborn E, Spiro T, for the Prothrombin Time Field Laboratories. Rivaroxaban calibrators and control sets measuring Rivaroxaban plasma concentrations using the prothrombin time. In: 21st International Congress on Thrombosis. Milan; 2010.
33. Gruber A., Marzec U.M., Buetehorn U., Hanson S., Perzborn E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of Rivaroxaban in primates. ASH Annual Meeting Abstract 2008, 112:3895.
34. Gerotziafas G.T., Elalamy I., Depasse F., Perzborn E., Samama M.M. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor Rivaroxaban. J Tromb Haemost 2007, 5:88.
35. Weitz J.I. New oral anticoagulants in development. Thromb Haemost 2010, 103:62-70.
36. McCullagh L., Tilson L., Walsh C., Barry M. A cost-effectiveness model comparing Rivaroxaban and Dabigatran Etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009, 27:829-846.
37. Wolowacz S.E., Roskell N.S., Maciver F., Beard S.M., Robinson P.A., Plumb J.M., et al. Economic evaluation of Dabigatran Etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009, 31:194-212.